Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474107 | 0.88 | PTGS2 (0.46) | PTGS2PTGS1PDE3A | |
| SCHEMBL2475949 | 0.86 | PTGS2 (0.47) | PTGS2MAPK14MAPK9MAPK10CSNK1D | |
| SCHEMBL2471849 | 0.80 | PTGS2 (0.51) | PTGS2MAPK14MAPK9MAPK10CSNK1D | |
| SCHEMBL2318797 | 0.75 | PTGS2 (0.52) | PTGS2MAPK14MAPK9MAPK10CSNK1D | |
| SCHEMBL2469059 | 0.74 | PTGS2 (0.64) | PTGS2MAPK10PTGS1LMNA | |
| SCHEMBL4680304 | 0.73 | MAPK14 (0.45) | PTGS2MAPK14MAPK9MAPK10CSNK1D | |
| SCHEMBL4974520 | 0.73 | PTGS2 (0.35) | PTGS2MAPK14MAPK9MAPK10CSNK1D | |
| SCHEMBL2471438 | 0.71 | MCHR1 (0.39) | PTGS2MAPK14MAPK9MAPK10CSNK1D | |
| SCHEMBL2471843 | 0.69 | RXFP1 (0.40) | PTGS2MAPK14CSNK1DPTGS1PDE3A | |
| SCHEMBL2471415 | 0.69 | LMNA (0.53) | PTGS2PTGS1PDE3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968973-B1 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| CN-101351461-B | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN LA ROCHE | 2011-09-07 | — | — | CN | disclosed |
| CN-101351461-A | Aryl-iso oxazol-4-yl-imidazole derivatives | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | CN | disclosed |
| EP-1968973-A2 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-7414061-B2 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007074078-A2 | ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161654-A1 | Aryl-isoxazol-4-yl-imidazole derivatives | GABRA5, GABRA4, GABRA1 | PTGS2 3762/4885MAPK14 4327/4885MAPK9 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.